{"id":65049,"date":"2026-05-12T14:51:31","date_gmt":"2026-05-12T06:51:31","guid":{"rendered":"https:\/\/flcube.com\/?p=65049"},"modified":"2026-05-12T14:51:32","modified_gmt":"2026-05-12T06:51:32","slug":"hybio-pharmaceutical-expands-torrent-pharma-partnership-with-lanreotide-acetate-for-u-s-market","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=65049","title":{"rendered":"Hybio Pharmaceutical Expands Torrent Pharma Partnership with Lanreotide Acetate for U.S. Market"},"content":{"rendered":"\n<p><strong>Hybio Pharmaceutical Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/300199:SHE\">SHE: 300199<\/a>) announced an expanded strategic partnership with <strong>Torrent Pharmaceuticals Inc.<\/strong>, extending their collaboration beyond the previously agreed <strong>abaloparatide<\/strong> to include <strong>lanreotide acetate sustained-release injection<\/strong> in pre-filled syringe formulation. Under the new agreement, <strong>Hybio will handle technology development and manufacturing supply<\/strong>, while <strong>Torrent secures exclusive U.S. commercialization rights<\/strong> for the long-acting somatostatin analogue.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-partnership-expansion-details\">Partnership Expansion Details<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Parties<\/strong><\/td><td>Hybio Pharmaceutical Co., Ltd. (SHE: 300199) and Torrent Pharmaceuticals Inc.<\/td><\/tr><tr><td><strong>Previous Collaboration<\/strong><\/td><td>Abaloparatide (osteoporosis treatment)<\/td><\/tr><tr><td><strong>New Asset<\/strong><\/td><td>Lanreotide acetate sustained-release injection (pre-filled syringe)<\/td><\/tr><tr><td><strong>Hybio Responsibilities<\/strong><\/td><td>Technology development and manufacturing supply<\/td><\/tr><tr><td><strong>Torrent Rights<\/strong><\/td><td>Exclusive commercialization in U.S. market<\/td><\/tr><tr><td><strong>Therapeutic Indications<\/strong><\/td><td>Acromegaly and certain neuroendocrine tumors<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-product-profile-amp-innovation\">Product Profile &amp; Innovation<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule Type:<\/strong> Long-acting somatostatin analogue<\/li>\n\n\n\n<li><strong>Formulation:<\/strong> Sustained-release injection in pre-filled syringe<\/li>\n\n\n\n<li><strong>Key Advantages:<\/strong> Convenient administration, improved patient compliance, reduced injection frequency<\/li>\n\n\n\n<li><strong>Reference Product:<\/strong> Somatuline Depot (Ipsen) \u2013 annual U.S. sales exceeding $500 million<\/li>\n\n\n\n<li><strong>Manufacturing Complexity:<\/strong> High-barrier peptide synthesis and sustained-release formulation technology<\/li>\n\n\n\n<li><strong>Patient Population:<\/strong> Acromegaly affects ~25,000 Americans; neuroendocrine tumors represent orphan indication with high unmet need<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-significance\">Strategic Significance<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Aspect<\/th><th>Details<\/th><\/tr><\/thead><tbody><tr><td><strong>U.S. Market Access<\/strong><\/td><td>Leverages Torrent&#8217;s established commercial infrastructure and regulatory expertise<\/td><\/tr><tr><td><strong>Manufacturing Leadership<\/strong><\/td><td>Validates Hybio&#8217;s capabilities in complex peptide therapeutics and advanced delivery systems<\/td><\/tr><tr><td><strong>Partnership Evolution<\/strong><\/td><td>Demonstrates successful execution of initial abaloparatide collaboration leading to expanded relationship<\/td><\/tr><tr><td><strong>Orphan Drug Opportunity<\/strong><\/td><td>Neuroendocrine tumor indication provides potential for premium pricing and market exclusivity<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p>The expanded partnership positions Hybio as a strategic manufacturing partner for complex injectable therapeutics, while providing Torrent with access to high-value specialty products for the U.S. market.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-outlook\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Somatostatin Analogue Market:<\/strong> Global market projected to reach $2.5 billion by 2030, driven by expanding indications and improved formulations<\/li>\n\n\n\n<li><strong>Competitive Landscape<\/strong> | Limited competition in sustained-release lanreotide segment; Ipsen maintains dominant market position<\/li>\n\n\n\n<li><strong>Regulatory Pathway<\/strong> | ANDA or 505(b)(2) pathway likely, depending on formulation differences from reference product<\/li>\n\n\n\n<li><strong>Revenue Potential<\/strong> | Estimated peak annual revenue of $100\u2013150 million for U.S. market opportunity<\/li>\n\n\n\n<li><strong>Strategic Value<\/strong> | Strengthens Hybio&#8217;s position as preferred CDMO partner for complex generic and biosimilar injectables<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding partnership agreements, development timelines, regulatory pathways, and commercial expectations for lanreotide acetate. Actual results may differ due to risks including regulatory decisions, competitive dynamics, manufacturing challenges, and market adoption rates.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Hybio Pharmaceutical Co., Ltd. (SHE: 300199) announced an expanded strategic partnership with Torrent Pharmaceuticals Inc.,&#8230;<\/p>\n","protected":false},"author":1,"featured_media":65050,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[287,24,1106,4736],"class_list":["post-65049","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-hybio-pharmaceutical","tag-rare-orphan-disease-drugs","tag-she-300199","tag-torrent-pharmaceuticals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Hybio Pharmaceutical Expands Torrent Pharma Partnership with Lanreotide Acetate for U.S. Market - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Hybio Pharmaceutical Co., Ltd. (SHE: 300199) announced an expanded strategic partnership with Torrent Pharmaceuticals Inc., extending their collaboration beyond the previously agreed abaloparatide to include lanreotide acetate sustained-release injection in pre-filled syringe formulation. Under the new agreement, Hybio will handle technology development and manufacturing supply, while Torrent secures exclusive U.S. commercialization rights for the long-acting somatostatin analogue.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=65049\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Hybio Pharmaceutical Expands Torrent Pharma Partnership with Lanreotide Acetate for U.S. Market\" \/>\n<meta property=\"og:description\" content=\"Hybio Pharmaceutical Co., Ltd. (SHE: 300199) announced an expanded strategic partnership with Torrent Pharmaceuticals Inc., extending their collaboration beyond the previously agreed abaloparatide to include lanreotide acetate sustained-release injection in pre-filled syringe formulation. Under the new agreement, Hybio will handle technology development and manufacturing supply, while Torrent secures exclusive U.S. commercialization rights for the long-acting somatostatin analogue.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=65049\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-12T06:51:31+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-12T06:51:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/1203.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65049#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65049\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Hybio Pharmaceutical Expands Torrent Pharma Partnership with Lanreotide Acetate for U.S. Market\",\"datePublished\":\"2026-05-12T06:51:31+00:00\",\"dateModified\":\"2026-05-12T06:51:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65049\"},\"wordCount\":385,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65049#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/1203.webp\",\"keywords\":[\"Hybio Pharmaceutical\",\"Rare \\\/ orphan disease drugs\",\"SHE: 300199\",\"Torrent Pharmaceuticals\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=65049#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65049\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=65049\",\"name\":\"Hybio Pharmaceutical Expands Torrent Pharma Partnership with Lanreotide Acetate for U.S. Market - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65049#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65049#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/1203.webp\",\"datePublished\":\"2026-05-12T06:51:31+00:00\",\"dateModified\":\"2026-05-12T06:51:32+00:00\",\"description\":\"Hybio Pharmaceutical Co., Ltd. (SHE: 300199) announced an expanded strategic partnership with Torrent Pharmaceuticals Inc., extending their collaboration beyond the previously agreed abaloparatide to include lanreotide acetate sustained-release injection in pre-filled syringe formulation. Under the new agreement, Hybio will handle technology development and manufacturing supply, while Torrent secures exclusive U.S. commercialization rights for the long-acting somatostatin analogue.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65049#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=65049\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65049#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/1203.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/1203.webp\",\"width\":1080,\"height\":608,\"caption\":\"Hybio Pharmaceutical Expands Torrent Pharma Partnership with Lanreotide Acetate for U.S. Market\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65049#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Hybio Pharmaceutical Expands Torrent Pharma Partnership with Lanreotide Acetate for U.S. Market\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Hybio Pharmaceutical Expands Torrent Pharma Partnership with Lanreotide Acetate for U.S. Market - Insight, China&#039;s Pharmaceutical Industry","description":"Hybio Pharmaceutical Co., Ltd. (SHE: 300199) announced an expanded strategic partnership with Torrent Pharmaceuticals Inc., extending their collaboration beyond the previously agreed abaloparatide to include lanreotide acetate sustained-release injection in pre-filled syringe formulation. Under the new agreement, Hybio will handle technology development and manufacturing supply, while Torrent secures exclusive U.S. commercialization rights for the long-acting somatostatin analogue.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=65049","og_locale":"en_US","og_type":"article","og_title":"Hybio Pharmaceutical Expands Torrent Pharma Partnership with Lanreotide Acetate for U.S. Market","og_description":"Hybio Pharmaceutical Co., Ltd. (SHE: 300199) announced an expanded strategic partnership with Torrent Pharmaceuticals Inc., extending their collaboration beyond the previously agreed abaloparatide to include lanreotide acetate sustained-release injection in pre-filled syringe formulation. Under the new agreement, Hybio will handle technology development and manufacturing supply, while Torrent secures exclusive U.S. commercialization rights for the long-acting somatostatin analogue.","og_url":"https:\/\/flcube.com\/?p=65049","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-05-12T06:51:31+00:00","article_modified_time":"2026-05-12T06:51:32+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/1203.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=65049#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=65049"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Hybio Pharmaceutical Expands Torrent Pharma Partnership with Lanreotide Acetate for U.S. Market","datePublished":"2026-05-12T06:51:31+00:00","dateModified":"2026-05-12T06:51:32+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=65049"},"wordCount":385,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=65049#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/1203.webp","keywords":["Hybio Pharmaceutical","Rare \/ orphan disease drugs","SHE: 300199","Torrent Pharmaceuticals"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=65049#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=65049","url":"https:\/\/flcube.com\/?p=65049","name":"Hybio Pharmaceutical Expands Torrent Pharma Partnership with Lanreotide Acetate for U.S. Market - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=65049#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=65049#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/1203.webp","datePublished":"2026-05-12T06:51:31+00:00","dateModified":"2026-05-12T06:51:32+00:00","description":"Hybio Pharmaceutical Co., Ltd. (SHE: 300199) announced an expanded strategic partnership with Torrent Pharmaceuticals Inc., extending their collaboration beyond the previously agreed abaloparatide to include lanreotide acetate sustained-release injection in pre-filled syringe formulation. Under the new agreement, Hybio will handle technology development and manufacturing supply, while Torrent secures exclusive U.S. commercialization rights for the long-acting somatostatin analogue.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=65049#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=65049"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=65049#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/1203.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/1203.webp","width":1080,"height":608,"caption":"Hybio Pharmaceutical Expands Torrent Pharma Partnership with Lanreotide Acetate for U.S. Market"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=65049#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Hybio Pharmaceutical Expands Torrent Pharma Partnership with Lanreotide Acetate for U.S. Market"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/1203.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65049","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=65049"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65049\/revisions"}],"predecessor-version":[{"id":65051,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65049\/revisions\/65051"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/65050"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=65049"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=65049"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=65049"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}